Dashboard Tools Market News Investing Ideas Pricing About Us
Sign Up
Log in
Lineage Cell Therapeutics Inc banner
L

Lineage Cell Therapeutics Inc
F:BT3

Watchlist Manager
Lineage Cell Therapeutics Inc
F:BT3
Watchlist
Price: 1.39 EUR -3.47% Market Closed
Market Cap: €262.4m
Write Note Create Alert Ask AI
Price Target
Loading...
Revenue
Loading...
Operating Income
Loading...
Net Income
Loading...

Wall Street
Price Targets

BT3 Price Targets Summary
Lineage Cell Therapeutics Inc

Wall Street analysts forecast BT3 stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for BT3 is 3.34 EUR with a low forecast of 1.59 EUR and a high forecast of 7.42 EUR.

BT3 Lowest Forecast
Wall Street Target
1.59 EUR
14% Upside
BT3 Average Forecast
Wall Street Target
3.34 EUR
140% Upside
BT3 Highest Forecast
Wall Street Target
7.42 EUR
434% Upside
Lowest
Price Target
1.59 EUR
14% Upside
Average
Price Target
3.34 EUR
140% Upside
Highest
Price Target
7.42 EUR
434% Upside
Lineage Cell Therapeutics Inc Competitors:
Price Targets
MASI
Masimo Corp
37% Upside
HCAT
Health Catalyst Inc
84% Upside
CFFN
Capitol Federal Financial Inc
4% Upside
MASI
Masimo Corp
37% Upside
HCAT
Health Catalyst Inc
84% Upside
CFFN
Capitol Federal Financial Inc
4% Upside

Revenue
Forecast

6% / Year
Past Growth
58% / Year
Estimated Growth
Estimates Accuracy
1%
Average Beat
6% / Year
Past Growth
58% / Year
Estimated Growth
Estimates Accuracy
1%
Average Beat

For the last 13 years the compound annual growth rate for Lineage Cell Therapeutics Inc's revenue is 6%. The projected CAGR for the next 4 years is 58%.

What are analyst estimates?

Operating Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-1%
Average Miss
N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-1%
Average Miss

What are analyst estimates?

Net Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-38%
Average Miss
N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-38%
Average Miss

What are analyst estimates?

See Also

Summary
BT3 intrinsic value, competitors valuation, and company profile.
DCF Valuation
BT3 stock valuation using Discount Cash Flow valuation method.
Relative Valuation
BT3 stock valuation using valuation multiples.
Wall Street Estimates
BT3 price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
BT3 stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is BT3's stock price target?
Price Target
3.34 EUR

According to Wall Street analysts, the average 1-year price target for BT3 is 3.34 EUR with a low forecast of 1.59 EUR and a high forecast of 7.42 EUR.

What is Lineage Cell Therapeutics Inc's Revenue forecast?
Projected CAGR
58%

For the last 13 years the compound annual growth rate for Lineage Cell Therapeutics Inc's revenue is 6%. The projected CAGR for the next 4 years is 58%.

Back to Top
ALPHA SPREAD
Follow us
Join more than 316,200+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2026 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.